Tratamiento antimicrobiano en las agudizaciones de la Enfermedad Pulmonar Obstructiva Crónica

Referencias bibliográficas

• Rabe K, Hurd S, Anzuelo A, Barnes PJ, Buist SA, Calverley P et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532–55.
• Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006;28: 523–32.
• Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbations frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847- 52.
• Miravtilles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F et al. Effect of exacerbations on quality of life in patients with COPD: a 2 year follow up study. Thorax 2004; 59: 387-95.
• Soler Cataluña JJ, Martinez- Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with COPD. Thorax 2005; 60: 925-31.
• Miravitlles M, Murio C, Guerrero T, Gisbert R, on behalf of the DAFNE study group. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002;121:1449-55.
• Miravitlles M. El fracaso en el tratamiento de las agudizaciones de la enfermedad pulmonar obstructiva crónica. Factores de riesgo e importancia clínica. Med Clin (Barc) 2002;119:304-14.
• Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173:1114–21.
• Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH investigators. Salmeterol and fluticasone proprionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775–89.
• Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc Vol 4. pp 554–564, 2007.
• Connors AF Jr, Dawson NV, Thomas C, Harrell FE Jr, Desbiens N, Fulkerson WJ et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease: the SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996;154:959–67.
• Hurst JR, Perera WR, Wilkinson TM, Donaldson GC, Wedzicha JA. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:71–8.
• Sethi S, Evans N, Grant BJB, Murphy TF. Acquisition of a new bacterial strain and occurrence of exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;347:465–71.
• Wood-Baker RR, Gibson PG, Hannay M, Walters EH, Walters JAE. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;1:CD001288.
• Quon BS, Gan WQ, Sin DD. Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis. Chest 2008;133;756-66.
• Ram FSF, Picot J, Lightowler J, Wedzicha JA. Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews 2004;3:CD004104.
• McCrory DC, Brown CD. Anti-cholinergic bronchodilators versus B_2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002;4:CD003900.
• Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbation of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
• Ram FSF, Rodriguez-Roisin R, Granados-Navarrete A, GarciaAymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Syst Rev 2006, Apr 19(2): CD 004403.
• Miravitlles M. Exacerbations of chronic obstructive pulmonary disease. When are bacteria important? Eur Respir J 2002;20 (suppl);36:9S-19S.
• Stolz D, Chris-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C, et al. Antibiotic treatment of exacerbations of COPD: a randomized controlled trial comparing procalcitonin guidance with standard therapy. Chest 2007; 131: 9-19.
• Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother 2002; 49:897-903.
• El Moussaoui,R, Roede BM, Speelman P, Bresser P, Prins JM, Bossuyt PMM. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax 2008;63:415–22.
• Miravitlles M, Monsó E, Mensa J, Aguaron J, Barbera J, Barcena M et al. Tratamiento antimicrobiano de la agudización de la EPOC: Documento de consenso 2007. Arch Bronconeumol 2008;44(2):100-8.
• Pérez-Trallero E, García de la Fuente C, García-Rey C, Baquero F, Aguilar L, Dal-Ré R, et al. Spanish Surveillance Group for Respiratory Pathogens. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005;49:1965-72.
• Andes D. Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2001;14:165-72.
• Soriano F, Granizo JJ, Coronel P, Gimeno M, Ródenas E, Gracia M, et al. Antimicrobial susceptibility of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis isolated from adult patients with respiratory tract infections in four southern European countries. The ARISE project. Int J Antimicrob Agents 2004; 23:296-9.
• Bouza E, García-Garrote F, Cercenado E, Marín M, Díaz MS. Pseudomonas aeruginosa: a survey of resistance in 136 hospitals in Spain. The Spanish Pseudomonas aeruginosa Study Group. Antimicrob Agents Chemother 1999; 43:981-2.
• Guía de práctica clínica de diagnóstico y tratamiento de la Enfermedad Pulmonar Obstructiva Crónica. SEPAR-ALAT, 2007. Arch Bronconeumol 2008;44(5)271-81. www.separ.es.
• GOLD executive committe. Global Initiative for Chronic Obstructive Pulmonary Disease. Update 2007. Accesible en: www.goldcopd.com.
• Celli BR, Macnee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23(6):932-46.
• Poole PJ, Chacko E, Wood-Baker RWB, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2006;(1): CD002733.
• Alfageme I, Vazquez R, Reyes N, Muñoz J, Fernández A, Hernández M et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006;61(3):189-95.
• Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 15: 957-965.
• Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JAD Jr, Korducki L et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergics bronchodilator. Ann Intern Med 2005; 143: 319-26.
• Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. TORCH investigators. Salmeterol and fluticasone proprionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-89.
• Steurer-Stey C, Bachmann LM, Steurer J, Tramèr MR. Oral purified bacterial extracts in chronic bronchitis and COPD. Chest 2004;126:1645-55.
• Álvarez-Mon M, Miravitlles M, Morera J, Callol L, Álvarez-Sala JL. Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with chronic obstructive pulmonary disease. Chest 2005;127:1212-8.